Contact
Please use this form to send email to PR contact of this press release:
Aclaris Therapeutics Provides Update on Oral and Topical JAK 1/3 Inhibitor Clinical Trials
TO:
Please use this form to send email to PR contact of this press release:
Aclaris Therapeutics Provides Update on Oral and Topical JAK 1/3 Inhibitor Clinical Trials
TO: